| Browse All

Vyome Holdings, Inc. (HIND)

Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
2.21 USD -0.01 (-0.450%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 2.21

Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:51 p.m. EDT

Vyome Holdings, Inc. (HIND) is currently in a highly volatile and declining trend, with a recent price of $2.19, significantly below its 52-week low of $1.75. The stock has shown a consistent downward movement over the past 14 days, indicating weak momentum and potential short-term risks. The short-term forecasting model suggests a slight upward movement of 2.74%, but this is not enough to offset the overall bearish sentiment. The stock's fundamentals are also concerning, with a negative trailing EPS, low revenue growth, and a high price-to-sales ratio. Additionally, there are no dividends to consider, making it unsuitable for income-focused investors. Given the lack of momentum and poor fundamentals, this stock is not recommended for short-term or long-term investment at this time.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.155274
MSTL0.156848
AutoTheta0.174530
AutoARIMA0.294604

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 55%
H-stat 2.75
Ljung-Box p 0.000
Jarque-Bera p 0.192
Excess Kurtosis -0.94
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.831
Revenue per Share 0.148
Market Cap 15,510,947
Website https://www.vyometx.com

Info Dump

Attribute Value
52 Week Change -0.94203657
Address1 Harvard Square
Address2 One Mifflin Place Suite 400
All Time High 138,156,000.0
All Time Low 1.75
Ask 2.85
Ask Size 2
Average Daily Volume10 Day 17,980
Average Daily Volume3 Month 869,626
Average Volume 869,626
Average Volume10Days 17,980
Bid 1.65
Bid Size 2
Book Value 0.413
City Cambridge
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.21
Current Ratio 1.988
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 2.33
Day Low 2.2
Debt To Equity 0.831
Display Name Vyome
Earnings Timestamp End 1,763,064,000
Earnings Timestamp Start 1,763,064,000
Ebitda -2,735,052
Ebitda Margins 0.0
Enterprise To Ebitda -4.344
Enterprise To Revenue 37.158
Enterprise Value 11,879,830
Eps Trailing Twelve Months -4.86
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.5204
Fifty Day Average Change -0.3104
Fifty Day Average Change Percent -0.12315506
Fifty Two Week Change Percent -94.20366
Fifty Two Week High 56.4
Fifty Two Week High Change -54.190002
Fifty Two Week High Change Percent -0.9608156
Fifty Two Week Low 1.75
Fifty Two Week Low Change 0.46000004
Fifty Two Week Low Change Percent 0.26285717
Fifty Two Week Range 1.75 - 56.4
Financial Currency USD
First Trade Date Milliseconds 1,475,760,600,000
Float Shares 3,254,351
Free Cashflow 5,105,984
Full Exchange Name NasdaqCM
Full Time Employees 9
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.68427
Gross Profits 218,771
Has Pre Post Market Data 1
Held Percent Insiders 0.33918
Held Percent Institutions 0.015470001
Implied Shares Outstanding 7,018,528
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,755,216,000
Last Split Factor 1:4
Long Business Summary Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Long Name Vyome Holdings, Inc.
Market us_market
Market Cap 15,510,947
Market State CLOSED
Max Age 86,400
Message Board Id finmb_115222623
Most Recent Quarter 1,767,139,200
Net Income To Common -10,262,007
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 15,791,688
Number Of Analyst Opinions 1
Open 2.26
Operating Cashflow -3,748,853
Operating Margins -37.07351
Payout Ratio 0.0
Phone 973-832-8147
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 2.21
Post Market Time 1,776,465,880
Previous Close 2.22
Price Hint 4
Price To Book 5.35109
Price To Sales Trailing12 Months 48.515068
Profit Margins 0.0
Quick Ratio 1.858
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.00999999
Regular Market Change Percent -0.45045
Regular Market Day High 2.33
Regular Market Day Low 2.2
Regular Market Day Range 2.2 - 2.33
Regular Market Open 2.26
Regular Market Previous Close 2.22
Regular Market Price 2.21
Regular Market Time 1,776,456,001
Regular Market Volume 21,450
Return On Assets -0.43583
Revenue Growth -0.405
Revenue Per Share 0.148
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 7,018,528
Shares Percent Shares Out 0.0226
Shares Short 158,474
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 208,107
Short Name Vyome Holdings, Inc.
Short Percent Of Float 0.0352
Short Ratio 3.87
Source Interval 15
State MA
Symbol HIND
Target High Price 15.0
Target Low Price 15.0
Target Mean Price 15.0
Target Median Price 15.0
Total Cash 4,982,333
Total Cash Per Share 0.71
Total Debt 31,258
Total Revenue 319,714
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.86
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.51431
Two Hundred Day Average Change -3.3043098
Two Hundred Day Average Change Percent -0.59922457
Type Disp Equity
Volume 21,450
Website https://www.vyometx.com
Zip 2,138